Exposure of patients to the dangers of certain diagnostic equipment can have unwanted long-term effects, which healthcare providers may be underestimating, according to research conducted at the University of Saskatchewan.
Diagnostic tools have been a tremendous force in diminishing the rate of cancer mortality in the United States. Earlier screening and improved technology have together helped diagnosis of early-stage cancers, when the disease is still responsive to treatment. However, exposure of patients to the dangers of certain diagnostic equipment can have unwanted long-term effects, which healthcare providers may be underestimating, according to a new study in the Journal of Medical Imaging and Radiation Sciences.
Researchers from the University of Saskatchewan surveyed the awareness of healthcare professionals—physicians, radiologists, and technologists—regarding the actual dose of radiation that patients are exposed to during a computed tomography (CT) scan. The survey found that while 73% of physicians, 97% of radiologists, and 76% of technologists correctly identified that there is an increased cancer risk from one abdominal-pelvic CT, only 18% of physicians, 28% of radiologists, and 22% of technologists were able to correctly identify the dose in relation to chest x-rays. A significant portion of respondents underestimated the dose that patients receive.
This is a problem, according to the study’s lead author David Leswick, MD, FRCPC, Department of Medical Imaging, College of Medicine, University of Saskatchewan. “Underestimating radiation dose from a CT scan is more concerning than knowing the exact dose level, particularly when it is a vast underestimation, as this may lead to minimization of the risk estimate when considering a test,” Leswick said in a statement.
He explained that the risk of fatal malignancy following a 10-mSv dose of radiation (nearly equivalent to what a patient receives when undergoing an abdomen-pelvis CT) may be as high as 1 in a 1000. This is significant, he said, considering that 2% of cancers in the United States can be attributed to CT.
Healthcare providers, the survey found, also lacked an understanding of the energy source used by other diagnostic equipment, such as magnetic resonance imaging (MRI) and ultrasound, neither of which use ionizing radiation. Yet 20% of physicians, 6% of radiologists, and 7% of technologists attributed radiation exposure to MRIs, and 11% of physicians and 7% of technologists believed an ultrasound used radiation. This false belief could result in underutilization of these modes of imaging, Leswick said.
He believes, “It is important for healthcare professionals to be aware of radiation dose levels and risks from imaging tests for several reasons, including the ability to weigh the risks and benefits of tests, counsel patients on relevant risks, optimize protocols to minimize radiation dose, and select appropriate protocols to minimize radiation dose.”
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More